Tag : EGFR MUTATION

CONFERENCE UPDATE

Resectable NSCLC in transition: Integrating immunotherapy and targeted approaches
The landscape of early-stage non-small cell lung cancer is undergoing a rapid transformation. Once defined by the modest survival gains of adjuvant chemotherapy, treatment strategies now extend to immunotherapy and targeted therapies in both adjuvant and neoadjuvant settings.
NEWS AND PERSPECTIVE

FDA approves the addition of chemotherapy to osimertinib in EGFRm advanced lung cancer
Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).
NEWS AND PERSPECTIVE

FDA approves amivantamab + chemotherapy in NSCLC with EGFR exon 20 insertion mutations
Alterations in the epidermal growth factor receptor (EGFR) gene occur in up to 40% of non-small cell lung cancers (NSCLCs), among which exon 20 insertions are the third most common type of mutation and account for up to 12% of EGFR-mutated (EGFRm) cases.